Form 8-K Blueprint Medicines Corp For: Feb 21
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Blueprint Medicines (BPMC) PT Raised to $98 at Wedbush
February 22, 2018 3:28 PM ESTWedbush raised its price target on Blueprint Medicines (NASDAQ: BPMC) to $98.00 (from $96.00) while maintaining a Outperform rating.
Analyst David Nierengarten commented, "In addition to working toward enrollment of the registration-directed PDGFR-driven GIST trial set to complete mid-year, BPMC has moved... More
